Are you Dr. Cefalu?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 34 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1450 Poydras St
New Orleans, LA 70112Phone+1 504-903-1932
Summary
- Dr. William Cefalu, MD is an endocrinologist in New Orleans, Louisiana. He is currently licensed to practice medicine in Louisiana, Vermont, and North Carolina. He is a Professor at Diabetes and Metabolism.
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1982 - 1986
- University of California (Irvine)Residency, Internal Medicine, 1981 - 1982
- Louisiana State University School of Medicine in New OrleansClass of 1980
Certifications & Licensure
- CA State Medical License 1981 - Present
- LA State Medical License 1979 - 2025
- VT State Medical License 1998 - 2010
- NC State Medical License 1988 - 1998
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Clinical Trials
- Chromium and Insulin Action Start of enrollment: 1998 Aug 01
- Effect of Chromium Picolinate on Insulin Sensitivity in Type 2 Diabetes Start of enrollment: 2003 Oct 01
- The Effect of Blueberries on Enhancing Insulin Sensitivity in Humans: A Pilot Study Start of enrollment: 2007 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- Response to Comment on Riddle et al. Diabetes Care Editors’ Expert Forum 2018: Managing Big Data for Diabetes Research and Care. Diabetes Care 2019;42:1136–1146Matthew C. Riddle, William T. Cefalu, Edward W. Gregg
Diabetes Care. 2019-11-01 - 5 citationsKnow Diabetes by HeartEduardo Sanchez, William T. Cefalu
Circulation. 2019-08-13 - 1943 citationsClinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in RangeTadej Battelino, Thomas Danne, Richard M. Bergenstal, Stephanie A. Amiel, Roy W. Beck
Diabetes Care. 2019-08-01
Press Mentions
- Loss-of-Function Mutation in Thiamine Transporter 1 in a Family with Autosomal Dominant DiabetesMarch 4th, 2020
- ASMBS Annual Meeting at ObesityWeek 2019December 1st, 2019
- AgeX Therapeutics to Present at Metabesity 2019October 11th, 2019
- Join now to see all
Grant Support
- Pregnane And Glycosides And Obesity/Llya RaskinNational Center For Complementary &Alternative Medicine2010–2011
- Integrative Biology Core/Thomas W. GettysNational Center For Complementary &Alternative Medicine2010–2011
- Botanical Research Core/David M. RibnickyNational Center For Complementary &Alternative Medicine2010–2011
- Artemisia SP And Insulin Action/William T. CefaluNational Center For Complementary &Alternative Medicine2010–2011
- Adipocytes And Botanicals/Jacequeline M. StephensNational Center For Complementary &Alternative Medicine2010–2011
- Botanicals And Metabolic SyndromeNational Center For Complementary &Alternative Medicine2005–2011
- Pmi-5011 And Insulin ActionNational Center For Complementary &Alternative Medicine2005–2009
- Chromium, Cellular Energy Status And Whole Body Energy BalanceNational Center For Complementary &Alternative Medicine2006–2007
- Administrative CoreNational Center For Complementary &Alternative Medicine2005–2007
- Chromium And Insulin ActionNational Institute Of Diabetes And Digestive And Kidney Diseases2003–2006
- Chromium, Cellular Energy Status, Whole Body Energy BalaNational Center For Complementary &Alternative Medicine2005
- HRT To Augment Loss Of Visceral Fat And Improve Insulin SensitivityNational Center For Research Resources2004–2005
- Effect Of Chromium Picolinate On Glucose Control In Type II Diabetic PatientsNational Center For Research Resources2004
- Chromium VS Factors Regulating Insulin Sensitivity In Type 2 DiabetesNational Center For Research Resources2004
- Changes In Body COMP. &Insulin Sens. On Cardiovascular Risk In Type 2 DiabetesNational Center For Research Resources2004
- Hormone Replacement For Prevention Of Visceral ObesityNational Institute On Aging2001–2002
- Effect Of Chromium Picolinate On Glucose Control In Type 2 Diabetic PatientsNational Center For Research Resources1999–2002
- Chromium And Insulin ActionNational Institute Of Diabetes And Digestive And Kidney Diseases2001
- Caloric Restriction, Aging, And Insulin ActionNational Institute On Aging1999–2001
- Comparison Of Glucotrol And Metformin Alone And Combined In Patients With NIDDMNational Center For Research Resources1997–2000
- Inhaled Human Insulin VS Usual SQ Insulin In Type II Diabetes MellitusNational Center For Research Resources1998–1999
- Inhaled Human Insulin VS Usual SQ Insulin In Type I Diabetes MellitusNational Center For Research Resources1998–1999
- Inhaled Human Insulin As Adjunctive Therapy In Subjects With Type 2 DiabetesNational Center For Research Resources1998–1999
- Nutritional Modulation Of Age Related ProcessesNational Center For Research Resources1996–1999
- Caloric Restriction, Aging And Cardiovascular DiseaseNational Institute On Aging1993–1998
- Caloric Restriction, Aging And Cardiovascular DiseaseNational Institute On Aging1997
- Norvasc As Alternate Therapy To Procardia XL Of Essential HypertensionNational Center For Research Resources1996–1997
- Effect Of Sulfonylurea On Tissue Sensitivity To Insulin In Diabetes MellitusNational Center For Research Resources1994–1997
- Comparison Trial Of Effects Of Estrogen And Hormone Replacement TherapyNational Center For Research Resources1994–1996
- Caloric Restriction And Cardiovascular AgingNational Institute On Aging1992–1996